Trials / Active Not Recruiting
Active Not RecruitingNCT05676931
Study With Various Immunotherapy Treatments in Participants With Lung Cancer
A Phase II, Open-label, Platform Study, to Evaluate Immunotherapy-based Combinations in Participants With Advanced Non-Small Cell Lung Cancer
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 400 (estimated)
- Sponsor
- Gilead Sciences · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the objective response rate (ORR) of immunotherapy-based combination therapy and to assess the safety and tolerability of immunotherapy-based combination therapy.
Detailed description
The study includes multiple substudy arms (Substudy A, B, C), which will evaluate immunotherapy-based combinations.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Domvanalimab | Administered as specified in the treatment arm |
| DRUG | Quemliclustat | Administered as specified in the treatment arm |
| DRUG | Zimberelimab | Administered as specified in the treatment arm |
| DRUG | Docetaxel | Administered as specified in the treatment arm |
| DRUG | Platinum-Based Doublet | Administered as specified in the treatment arm |
Timeline
- Start date
- 2023-02-21
- Primary completion
- 2027-12-01
- Completion
- 2027-12-01
- First posted
- 2023-01-09
- Last updated
- 2025-10-02
Locations
51 sites across 10 countries: United States, Australia, France, Georgia, Italy, Poland, South Korea, Spain, Taiwan, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05676931. Inclusion in this directory is not an endorsement.